Rapid Diagnosis of Viral Acute Respiratory Infection to Decrease Unnecessary Antibiotic Utilization in the Emergency Department (RADIATE)
Launched by CHRISTOPHER PAYETTE · Feb 15, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The clinical trial called RADIATE is studying a new way to quickly identify whether an acute respiratory infection is caused by a virus. This is important because many people with these infections go to the emergency department (ED) and are often given antibiotics, even though antibiotics are not effective against viral infections. By using a rapid test that can detect the viral cause of the illness, the goal is to help doctors make better decisions about treatment and reduce the unnecessary use of antibiotics. This can help prevent problems like antibiotic resistance, where bacteria become stronger and harder to treat.
To participate in the trial, individuals must be over 18 years old and have symptoms of a respiratory infection, such as a cough, runny nose, or fever, lasting less than 14 days. Participants will receive the rapid test in the ED, and if the test shows a viral infection, they may be less likely to receive antibiotics. This study aims to improve patient care in the ED while promoting responsible use of antibiotics. Remember, this trial is currently recruiting, so there may be opportunities to participate if you meet the eligibility criteria.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Over the age of 18
- • Clinical suspicion of an acute respiratory infection by an emergency department provider
- • Patient endorses at least ONE symptom of respiratory illness including: cough, sneezing, runny or stuffy nose, sore throat, headaches, muscle aches, trouble breathing, shortness of breath, fever
- • Patient reports symptoms lasting less than 14 days (i.e., no chronic symptoms)
- • Patient able to provide informed consent
- Exclusion Criteria:
- • Patient is a prisoner or ward of state
- • Patients that will get antibiotics regardless of of the results of the test (e.g. sepsis, hypoxia, shock, lobar pneumonia, altered mental status, meningitis, pyelonephritis, appendicitis or related, high clinical severity not otherwise specified
- • Patients who have tested positive for C. diff in the last 60 days
- • Patients who are hospitalized from the emergency department
- • Patients that have an oxygen saturation lower than 95% at triage
- • Altered mental status
About Christopher Payette
Christopher Payette is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With extensive experience in the pharmaceutical and biotechnology sectors, Payette leads initiatives focused on innovative therapies and treatments across various therapeutic areas. His expertise encompasses the design, execution, and management of clinical trials, ensuring adherence to regulatory standards and ethical guidelines. By fostering collaboration among stakeholders, including researchers, healthcare professionals, and regulatory bodies, Christopher Payette aims to drive the development of groundbreaking solutions that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Washington, District Of Columbia, United States
Patients applied
Trial Officials
Christopher Payette, MD
Principal Investigator
George Washington University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported